骨髓增生异常综合征的治疗现状及进展  

Standardized and novel treatments for patients with myelodysplastic syndromes:an update

作　　者：叶丽[1] 佟红艳[1] 

机构地区：[1]浙江大学医学院附属第一医院MDS诊治中心,浙江杭州310003

出　　处：《临床荟萃》2014年第10期1095-1099,共5页Clinical Focus

基　　金：国家自然科学基金(30870914;81270582);浙江省自然科学基金杰出青年项目(LR12H08001);浙江省科技厅重大项目(2013c03043-2);浙江省卫生厅支撑学科项目(201234445;2012ZDA013);浙江省中医药局(2012ZA071)

摘　　要：骨髓增生异常综合征(MDS)是一组起源于造血干细胞的恶性克隆性疾病,以骨髓衰竭和无效造血为特点,临床上多表现为持续血细胞减少,约1/3患者疾病进程中转化为急性白血病。目前该病尚缺乏有效特异的治疗方法,异基因造血干细胞移植是治愈的唯一手段。本文依据美国国立综合癌症网络(NCCN)指南、欧洲白血病工作组(European Leukemia Net,ELN)推荐及国内外的MDS专家共识,归纳了MDS的规范化治疗。同时,结合近几年临床研究,介绍了MDS一些治疗新进展。Myelodysplastic syndromes （MDS） are a complex group of hematopoietic stem cell disorders characterized by bone marrow failure and ineffective hematopoiesis.Clinically,MDS mainly presents as persistent hypocytomsis and a risk of developing into acute myeloid leukemia（AML）.Previously,supportive and palliative care is the primary treatment for MDS.Whereas,hematopoietic stem cell transplantation（HSCT） is now the only potentially curative option for patients with MDS.In this review,we summarized the standardized treatments for MDS according to the guidelines of National Comprehensive Cancer Network（NCCN） in U.S.,the recommendations of European Leukemia Net（ELN） and the consensus of MDS experts.Meanwhile,we introduced a series of novel treatments for MDS from some recent clinical trials.

关 键 词：骨髓增生异常综合征 造血干细胞移植 免疫抑制剂 

分 类 号：R551.3[医药卫生—血液循环系统疾病]